More than 50 biotech leaders and investors are urging the FDA to disregard a methodologically flawed report on mifepristone.

Our health care system needs to do a better job of diagnosing and supporting people with cannabis-related diseases,” a ...

As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...

A new large study from Denmark finds no evidence that aluminum salts used in vaccines are tied to a higher risk of childhood ...

The people most at risk from suicide aren’t adolescents in angst or those experiencing a midlife lull, but men age 75 and ...

A federal judge has tossed out a lawsuit from Humana that attempted to reinstate higher quality ratings to its 2025 Medicare ...

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...

Robert F. Kennedy Jr. just named Mark Cruz, a Klamath member, his top tribal health adviser. In a Q&A, Cruz emphasized tribal ...

The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, ...

A 51-year-old man died last month after receiving an experimental treatment from Sarepta, the third death this year tied to ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

Getting Coca-Cola to use cane sugar rather and ice cream manufacturers to stop their use of synthetic dyes are the latest ...